Effectors of epidermal growth factor receptor pathway: The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Shen, Yinchen ^a,b   Wang, Jianfei ^a,b   Han, Xiaohong ^a,b   Yang, Hongying ^a   Wang, Shuai ^a,b   Lin, Dongmei ^a   Shi, Yuankai ^a,b  

^a CANCER HOSPITAL   (China)

^b Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGE; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CODON; COLON CANCER; COLORECTAL CANCER; DISTANT METASTASIS; EXON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PIK3CA GENE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR DIFFERENTIATION; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84892425103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081628     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin. 63: 11-30.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
3. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
6. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
8. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
9. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et al. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4: e7287.
10. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefi t from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
11. De Roock W, Lambrechts D, Tejpar S (2009) K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 834.
12. Kumar K, Brim H, Giardiello F, Smoot DT, Nouraie M, et al. (2009) Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 15: 1155-1161.
13. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
14. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
15. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular Basis of Colorectal Cancer. N Engl J Med 361: 2449-2460.
16. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594-603.
17. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527.
18. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261.
19. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28: 466-474.
20. Mao C, Zhou J, Yang Z, Huang Y, Wu X, et al. (2012) KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer. PLoS One, 7: e36653.
21. Wang J, Yang H, Shen Y, Wang S, Lin D, et al. (2013) Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark. 13: 89-97.
22. Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, et al. (2011) Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol. 17: 809-816.
23. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324.
24. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.
25. Li HT, Lu YY, An YX, Wang X, Zhao QC (2011) KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep. 25: 1691-1697.
26. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, et al. (2008) High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13, 1270-1275.
27. Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, et al. (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin Oncol. 26, 4217-4219.
28. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648.
29. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, et al. (2008)Wild-type BRAF is required for response to panitumimab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712.
30. Rako I, Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S (2012) Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Neoplasma 59: 376-383.
31. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, et al. (2012) Racteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 413: 1605-1611.
32. Kim A, Lee JE, Lee SS, Kim C, Lee SJ, et al. (2013) Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer. 133: 984-996.
33. Zhao L, Vogt PK (2008) Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105: 2652-2657.
34. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, et al. (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41: 1649-1654.
35. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected coloncancer. J Clin Oncol 27: 1477-1484.
36. Liao W, Liao Y, Zhou JX, Xie J, Chen J, et al. (2010) Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anat Rec (Hoboken). 293: 1506-1511.
37. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, et al. (2013) PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clin Cancer Res. 19: 3285-3296.
38. Souglakos J, Philips J, Wang R, Marwah S, Silver M, et al. (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer101: 465-472.
39. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, et al. (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99: 83-89.
40. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, et al. (2011) Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in $2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 6: e15980.
41. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
42. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL (2012) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 23: 1518-1525.
43. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465.
44. Irahara N, Baba Y, Nosho K, Shima K, Yan L, et al. (2010) NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 19: 157-163.
45. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, et al. (2013) Massively parallel tumor multigene sequencing evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 19: 1902-1912.
46. Cancer Genome Atlas Network (2012) Comprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature. 487: 330-337.
47. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, et al. (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14: 749-759.
48. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381: 303-312.
49. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 304: 1812-1820.
50. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, et al. (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30: 3570-3577.